CHMA - Chiasma, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.48
-0.23 (-6.20%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close3.71
Open3.62
Bid3.45 x 2200
Ask10.15 x 800
Day's Range3.41 - 3.80
52 Week Range1.20 - 3.90
Volume98,136
Avg. Volume108,258
Market Cap84.865M
Beta (3Y Monthly)1.74
PE Ratio (TTM)N/A
EPS (TTM)-1.18
Earnings DateNov 7, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.50
Trade prices are not sourced from all markets
  • GlobeNewswire6 days ago

    Chiasma Announces Oral Presentation at the 18th Congress of the European Neuroendocrine Association

    Presentation by Dr. Maria Fleseriu, a widely-published endocrinologist and recognized thought leader in the field of acromegaly WALTHAM, Mass., Oct. 17, 2018 -- Chiasma,.

  • Benzinga21 days ago

    The Daily Biotech Pulse: TransEnterix's Positive Pre-Announcement, Merit Medical Opens Wallet, GW Pharma To Offer ADS Shares

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 1) Abbott Laboratories (NYSE: ABT ) AstraZeneca plc (NYSE: ...

  • GlobeNewswire22 days ago

    Chiasma Completes Enrollment of CHIASMA OPTIMAL Phase 3 Clinical Trial of Octreotide Capsules in Patients with Acromegaly

    Chiasma, Inc. (CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that it has completed enrollment of its international Phase 3 clinical trial, referred to as CHIASMA OPTIMAL (Octreotide capsules vs. Placebo Treatment In MultinationAL centers). This trial is being conducted under a Special Protocol Assessment (“SPA”) agreement with the U.S. Food and Drug Administration (“FDA”) to support potential regulatory approval in the United States of its investigational octreotide capsules, conditionally trade-named MYCAPSSA®, for the maintenance therapy of adult patients with acromegaly. Chiasma exceeded target enrollment of 50 patients in the trial with a total of 56 acromegaly patients randomized in 17 countries worldwide, including 21 patients from the U.S.

  • One Thing To Consider Before Buying Chiasma Inc (NASDAQ:CHMA)
    Simply Wall St.last month

    One Thing To Consider Before Buying Chiasma Inc (NASDAQ:CHMA)

    If you’re interested in Chiasma Inc (NASDAQ:CHMA), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impactRead More...

  • GlobeNewswirelast month

    Chiasma Announces Poster Presentation at the 9th International Congress of the Growth Hormone Research and IGF Societies

    Chiasma, Inc. (CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced a poster presentation at the 9th International Congress of the Growth Hormone Research and IGF Societies (GRS & IGF), which is being held September 14-17, 2018 in Seattle, WA. “For acromegaly patients with persistent disease following surgery, or for whom surgery is not an option, injectable somatostatin receptor ligands represent the current standard of care in the treatment of this rare but debilitating hormonal disorder,” commented William Ludlam, MD, PhD, Senior Vice President of Clinical Development and Medical Affairs at Chiasma.

  • Associated Press2 months ago

    Chiasma: 2Q Earnings Snapshot

    The Waltham, Massachusetts-based company said it had a loss of 36 cents per share. In the final minutes of trading on Thursday, the company's shares hit $1.25. A year ago, they were trading at $1.45. _____ ...

  • GlobeNewswire2 months ago

    Chiasma Reports Second Quarter 2018 Results

    Recent Highlights Include Completion of Enrollment of MPOWERED Phase 3 Trial and 50% Randomization in CHIASMA OPTIMAL Phase 3 Trial. WALTHAM, Mass., Aug. 09, 2018-- Chiasma, Inc., a clinical-stage biopharmaceutical ...

  • Associated Press5 months ago

    Chiasma: 1Q Earnings Snapshot

    The Waltham, Massachusetts-based company said it had a loss of 29 cents per share. In the final minutes of trading on Thursday, the company's shares hit $1.45. A year ago, they were trading at $1.60. _____ ...

  • Associated Press7 months ago

    Chiasma reports 4Q loss

    The Waltham, Massachusetts-based company said it had a loss of 25 cents per share. Losses, adjusted for restructuring costs, came to 21 cents per share. In the final minutes of trading on Tuesday, the ...

  • ACCESSWIRE7 months ago

    Blog Exposure - Chiasma to Present Design of Phase-3 Double-Blind Trial of Oral Octreotide Capsules Versus Placebo in Acromegaly Patients at ENDO 2018

    Stock Monitor: Akebia Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 20, 2018 / Active-Investors.com has just released a free research report on Chiasma, Inc. (NASDAQ: CHMA ). If ...

  • Want To Invest In Chiasma Inc (NASDAQ:CHMA)? Here’s How It Performed Lately
    Simply Wall St.7 months ago

    Want To Invest In Chiasma Inc (NASDAQ:CHMA)? Here’s How It Performed Lately

    Examining Chiasma Inc’s (NASDAQ:CHMA) past track record of performance is a valuable exercise for investors. It enables us to understand whether the company has met or exceed expectations, which isRead More...

  • Associated Press11 months ago

    Chiasma reports 3Q loss

    On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 28 cents. In the final minutes of trading on Thursday, the company's shares hit $2. A year ago, they were trading at ...

  • Is Chiasma Inc’s (CHMA) CEO Pay Fair?
    Simply Wall St.11 months ago

    Is Chiasma Inc’s (CHMA) CEO Pay Fair?

    Mark Fitzpatrick has been at the helm as CEO of Chiasma Inc (NASDAQ:CHMA), which has grown to a market capitalization of USD$51.16M. Recognizing whether CEO incentives are aligned with shareholdersRead More...